67Ga-DOTA-Lys(ALB)-GGNle-CycMSHhex

67Ga-DOTA-Lys(ALB)-GGNle-CycMSHhex is a **radiolabeled cyclic alpha-melanocyte stimulating hormone (α-MSH) peptide** specifically engineered for **melanoma imaging and potential targeted radionuclide therapy**. It utilizes a DOTA chelator for binding gallium-67, coupled to a cyclic hexapeptide analog of α-MSH via an albumin-binding moiety (Lys(ALB)), aiming to enhance pharmacokinetics by increasing blood retention and tumor targeting[3]. The peptide exhibits **high affinity** for the melanocortin-1 receptor (MC1R), which is highly overexpressed on melanoma cells but has limited expression in normal tissues, facilitating selective tumor imaging. Modifications such as albumin binding can reduce renal uptake and further improve tumor-to-background ratios. Developers have studied variants including 68Ga and 177Lu radiolabels, consistently showing robust melanoma targeting in preclinical models and first-in-human studies[2][3]. The main anticipated indication is the **detection and imaging of metastatic melanoma**, with investigational use for radionuclide therapy.

Other names

67Ga-DOTA-Lys(ALB)-GGNle-CycMSHhex